1. Exploring New Treatment Options for Relapsed/Refractory Hairy Cell Leukemia

2. This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. Overview of Hairy Cell Leukemia

4. Initial Treatment of Hairy Cell Leukemia Purine Analogs

5. Treatment of R/R Hairy Cell Leukemia

6. Moxetumomab Pasudotox-tdfk A Recombinant Immunotoxin Targeting CD22

7. Efficacy of Moxetumomab Pasudotox-tdfk in R/R Hairy Cell Leukemia

8. Safety of Moxetumomab Pasudotox-tdfk in R/R Hairy Cell Leukemia

9. FDA Approval of Moxetumomab Pasudotox-tdfk

10. Potential Future Directions

11. Potential Future Directions (cont)

12. Putting Data Into Practice Case 1

13. Nursing Considerations Cladribine and Rituximab in R/R HCL

14. Putting Data Into Practice Case 2

15. Selecting Patients for Moxetumomab Pasudotox-tdfk

16. Moxetumomab Pasudotox-tdfk Nursing Considerations

17. Monitoring for CLS and HUS is Essential

18. Using a Team-Based Approach to Optimize Outcomes in R/R Hairy Cell Leukemia

19. Points for Patient Education

20. Abbreviations

21. Abbreviations (cont)